Pfizer Ventures was among the investors in Triana’s series A round and has taken a board seat at the molecular glue platform developer.
US-based molecular glue developer Triana Biomedicines has publicly launched with $110m in series A funding provided by investors including pharmaceutical firm Pfizer’s corporate venturing unit, Pfizer Ventures.
The series A round was co-led by Lightspeed Venture Partners, RA Capital Management and Atlas Venture, with additional backing from Surveyor Capital and Logos Capital.
Triana is developing a discovery platform for molecular glue, a type of molecule that brings together proteins that do not normally interact, for use in a range of…
Fernando Moncada Rivera
Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
